Trial
NCT03793712
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
H. Lundbeck A/S
Collaborators
—
Condition
Schizophrenia
Intervention
Lu AF11167 (1-2 mg/day)
Why stopped
Lack of efficacy based on interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-23